Home > Healthcare > Pharmaceuticals > Finished Drug Form > Regenerative Medicine Market
Regenerative Medicine Market Share
- Report ID: GMI4571
- Published Date: Sep 2023
- Report Format: PDF
Regenerative Medicine Market Share
The key players in the regenerative medicine market are :
- Novartis AG
- Amgen, Inc.
- Bristol Myers Squibb
- BLUEBIRD BIO
- GC Pharma
- GlaxoSmithKline plc
- ANTEROGEN
- BIOSOLUTIONS
- TERUMO BCT
- AVITA MEDICAL
- Smith and Nephew
- ORGANOGENESIS
These companies are implementing several strategies such as collaborations, acquisitions, partnerships, mergers, and product launches to maintain a competitive edge in the industry.
Frequently Asked Questions (FAQ) :
The global regenerative medicine industry was worth USD 52.3 billion in 2022 and is projected to grow at CAGR of 20.4% through 2032, driven by the increasing product development activities and expanding clinical applications.
Musculoskeletal segment accounted for a major market share of 31.6% in 2022, backed by the increasing prevalence of musculoskeletal diseases such as osteoarthritis, rheumatoid arthritis, and several orthopedic disorders.
North America regenerative medicines market accounted for a revenue share of 45.5% in 2022 and will continue growth over 2023-2032, favored by the increasing adoption of innovative treatment therapies along with growing prevalence of chronic diseases.
Novartis AG, Amgen, Inc., Bristol Myers Squibb, BLUEBIRD BIO, GC Pharma, GlaxoSmithKline plc, ANTEROGEN, BIOSOLUTIONS, TERUMO BCT, AVITA MEDICAL, Smith and Nephew, and ORGANOGENESIS.
Regenerative Medicine Market Scope
×
Get a free sample of
Regenerative Medicine Market
Inquiry Before Buying
Get special pricing options on this report
Request Sectional Data
Over 70% of our clients customize reports to fit their needs. Please tell us how you would like to customize yours
below